Dri Healthcare Trust · TSX:DHT.U
Dri Healthcare Trust — Q2 2025 Earnings Presentation
15 slides from Dri Healthcare Trust's earnings presentation, Aug 14, 2025
Slide 1: Advancing Science in the Pharmaceutical and Biotechnology Sector
Advancing Science in the Pharmaceutical and Biotechnology Sector Q2 2025 Earnings Call | August 14, 2025 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by DRI Healthcare Trust (“DRI Healthcare”). DRI Healthcare is an unincorporated open-ended trust governed by the laws of the Province of Ontario, Canada. DRI Healthcare completed an initial public offering (the “IPO”) on February 11, 2021, in which it a
Slide 3: Gary Collins, Executive Chair
Gary Collins Executive Chair 3
Slide 4: Agenda
Agenda Gary Collins Executive Chair Internalization Update Ali Hedayat CEO Recent Highlights All Q&A Navin Jacob CIO Portfolio Update Amit Kapur CFO Financial Update 4
Slide 5: Internalization will lead to significant strategic benefits
Internalization will lead to significant strategic benefits Aligns stakeholder interests and yields higher cash returns $48 million termination fee, plus $1 million to purchase Cumulative savings anticipated1 relevant assets Completed July 1st All cash transaction has no impact on units outstand
Slide 6: Ali Hedayat, Chief Executive Officer
Ali Hedayat Chief Executive Officer 6
Slide 7: Recent Highlights
Recent Highlights Focus on asset strength, corporate structure and unitholder returns Portfolio Performance Manager Internalization Unitholder Value Assets tracking as anticipated Becoming an integrated organization Reactivated NCIB • Growth assets making continued • $49 million payment made on July
Slide 8: Navin Jacob, Chief Investment Officer
Navin Jacob Executive Vice President, Investments & Chief Investment Officer 8
Slide 9: Portfolio performance
Portfolio performance Portfolio assets show continued growth ($ millions) Q2 2025 Q2 2024 % Change1 Q1 2025 % Change1 TOTAL CASH RECEIPTS2 $40.2 $43.0 (7)% $62.0 (35)% - - n/a 5.0 (100) - - n/a - n/a 0.1 2.6 (94) 1.1 (87) 1.4 1.6 (12) 1.9 (24) 0.2 0.7 (68) 0.3 (20) 9.0 11.3 (20) 8.0 12 1.0 1.9 (45)
Slide 10: Robust pipeline of over $3 billion in potential opportunities
Address important unmet needs with life-changing therapies for patients Robust pipeline of over $3 billion Marketed by leading biotech or biopharma companies in potential opportunities1 Provides strong intellectual property and regulatory protection 1. As of August 13, 2025. Represents the aggregate
Slide 11: Amit Kapur, Chief Financial Officer
Amit Kapur Chief Financial Officer 11
Slide 12: Q2 2025 financial highlights
Q2 2025 financial highlights Total Cash Receipts1 Total Income Adjusted EBITDA1 $40.2 million $44.1 million $30.4 million -7% over Q2 2024 6% over Q2 2024 -8% over Q2 2024 Adjusted EBITDA Margin1 Adjusted Cash Earnings per Unit1 Declared Cash Distributions per Unit 76% $0.51 $0.10 1. Total Cash Rece
Slide 13: Strong cash generation
Strong cash generation Cash available to drive portfolio growth and maintain distributions to unitholders Adjusted EBITDA for the Last Twelve Months Ended June 30, 2025 ($M)1 Adjusted EBITDA Margin1 81% $186.8 $191.2 $185.7 $2.2 $0.7 $1.5 ($7.6) ($0.7) $2.8 ($22.1) ($13.3) $150.3 -- Adjusted Cash Ro
Slide 14: Well capitalized for growth
Well capitalized for growth Significant capacity for Cash and cash equivalents Royalties receivable Credit facility availability further $82.5 $49.6 $273.1 growth million1 million1 million1 1. As at June 30, 2025. 14
Slide 15: Key priorities
Rebuild trust with a focus on strong governance and tone from the top Key Invest in our people and build the priorities industry leading royalty investment team Execute on strong pipeline and operate at peak performance Focus on long-term, sustainable growth generating strong unitholder returns 15